Seladelpar, a PPAR-delta agonist, shows safety and improvement in primary biliary cholangitis (PBC) in a phase 3 study.

Seladelpar shows 'sustained improvement' in liver injury and pruritis markers in primary biliary cholangitis (PBC) patients, with 70% achieving primary study endpoint and 37.2% normalizing alkaline phosphatase in ongoing phase 3 ASSURE study. Seladelpar, a PPAR-delta agonist, demonstrates safety and tolerability through month 12, with clinically meaningful improvements in cholestasis and liver injury markers.

May 18, 2024
4 Articles